Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic‐phase chronic myeloid leukemia

Abstract

Although long-term outcomes were similar in CML-CP patients treated with each TKI regardless of first-line TKI selection, severe AEs in first-line TKI therapy decreased their survival rates. Early change in TKIs is recommended, when faced with severe AEs of specific TKIs.